Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 2
2011 2
2012 1
2013 1
2014 4
2015 4
2016 3
2017 4
2018 4
2019 1
2020 1
2021 5
2022 5
2023 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Comparing different robots available in the European market for the preparation of injectable chemotherapy and recommendations to users.
Cerutti A, Ledoux T, Vantard N, Cerfon MA, Kimbidima R, Larbre V, Herledan C, Lattard C, Baudouin A, Caffin AG, Schwiertz V, Ranchon F, Rioufol C. Cerutti A, et al. Among authors: vantard n. J Oncol Pharm Pract. 2023 Oct;29(7):1599-1612. doi: 10.1177/10781552221143786. Epub 2022 Dec 14. J Oncol Pharm Pract. 2023. PMID: 36999226 Review.
Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review.
Lattard C, Baudouin A, Larbre V, Herledan C, Cerutti A, Cerfon MA, Kimbidima R, Caffin AG, Vantard N, Schwiertz V, Ranchon F, Rioufol C. Lattard C, et al. Among authors: vantard n. J Cancer Res Clin Oncol. 2023 Aug;149(10):7905-7924. doi: 10.1007/s00432-023-04630-4. Epub 2023 Feb 28. J Cancer Res Clin Oncol. 2023. PMID: 36853384 Free PMC article.
Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, Vial T, Trillet-Lenoir V, Freyer G, Berard F, Rioufol C. Parel M, et al. Among authors: vantard n. BMC Pharmacol Toxicol. 2014 Jan 13;15:1. doi: 10.1186/2050-6511-15-1. BMC Pharmacol Toxicol. 2014. PMID: 24417770 Free PMC article.
Administration of anticancer drugs: exposure in hospital nurses.
Rioufol C, Ranchon F, Schwiertz V, Vantard N, Joue E, Gourc C, Gauthier N, Guedat MG, Salles G, Souquet PJ, Favier B, Gilles L, Freyer G, You B, Trillet-Lenoir V, Guitton J. Rioufol C, et al. Among authors: vantard n. Clin Ther. 2014 Mar 1;36(3):401-7. doi: 10.1016/j.clinthera.2014.01.016. Epub 2014 Mar 5. Clin Ther. 2014. PMID: 24612942
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Aussedat G, Maucort-Boulch D, Rey P, Safar V, Karlin L, Elsensohn MH, Bachy E, Lebras L, Favier B, Vantard N, Ghergus D, Golfier C, Sesques P, Lazareth A, Lequeu H, Ferrant E, Salles G, Nicolas-Virelizier E, Ghesquieres H. Aussedat G, et al. Among authors: vantard n. Leuk Lymphoma. 2022 Mar;63(3):599-607. doi: 10.1080/10428194.2021.1998483. Epub 2021 Oct 31. Leuk Lymphoma. 2022. PMID: 34720034
31 results